标题：嵌合抗原受体T细胞治疗非小细胞肺癌的现状和挑战

      作者：顾玲 综述 魏霄滢，衡伟 审校    苏州大学附属第一医院呼吸与危重症医学科，江苏 苏州 215000

      卷次： 2022年33卷19期

      【摘要】 嵌合抗原受体(chimeric antigen receptor，CAR)-T细胞治疗是继PD-1/PD-L1免疫检查点抑制剂之后，针对非小细胞肺癌等实体瘤免疫治疗的新探索。目前已有不少体外试验及动物试验发现靶向ROR1、PD-1/PD-L1、MSLN、EGFR等的CAR-T细胞可以通过直接杀伤肿瘤细胞和/或释放具有抗肿瘤活性的细胞因子达到抗肿瘤效应，但由于肿瘤免疫抑制的微环境、T细胞衰竭及CAR-T细胞免疫相关毒性反应等机制及应对策略尚不明确，临床研究尚未全面展开。就CAR-T细胞结构，非小细胞肺癌常见的肿瘤相关抗原，毒性反应发生机制等方面简述CAR-T细胞治疗的现状、挑战，为CAR-T细胞治疗进一步研究提供思路。
      【关键词】 嵌合抗原受体T细胞治疗；非小细胞肺癌；肿瘤相关抗原；免疫治疗相关毒性反应；联合治疗
      【中图分类号】 R734.2 【文献标识码】 A 【文章编号】 1003—6350（2022）19—2578—04

Chimeric antigen receptor T cell therapy of non-small cell lung cancer: condition and opportunity.
GU Ling, WEIXiao-ying, HENG Wei. Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of SoochowUniversity, Suzhou 215000, Jiangsu, CHINA【Abstract】 Chimeric antigen receptor (CAR)-T cell therapy is a novel immunotherapy for solid tumors such asnon-small cell lung cancer after PD-1/PD-L1 immune checkpoint inhibitors. In vitro, CAR-T cells targeting ROR1,PD-1/PD-L1, MSLN, EGFR can achieve anti-tumor effect by directly killing tumor cells and/or releasing cytokines.However, due to the unclear mechanisms of tumor immunosuppressive microenvironment and T cell exhaustion and thecoping strategies of CAR-T cell immune-related toxic reactions, clinical research has not been fully carried out. This pa-per briefly describes the current situation and challenges of CAR-T cell therapy in terms of CAR-T cell structure, com-mon tumor-associated antigens in non-small cell lung cancer, and the mechanism of toxic reactions, so as to provideideas for further research on CAR-T cell therapy.
      【Key words】 CAR-T cell therapy; Non-small cell lung cancer (NSCLC); Tumor-associated antigens; Immuno-therapy-related toxicity; Combination therapy　　　·综述·doi:10.3969/j.issn.1003-6350.2022.19.036